drugset / Trial / NCT03769766
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a prospective study to determine if the use of curcumin randomized against placebo will reduce cancer progression in patients with prostate cancer undergoing active surveillance.
Timeline
- Start
- 2019-03-11
- Primary completion
- 2029-11
- Completion
- 2030-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Curcumin | Small molecule | 500 mg | — |